The potency of Tube Pharmaceuticals GmbH's tubulysin toxin as a conjugate payload could allow the company to target resistant cancers. Tube is developing a polymer-tubulysin conjugate for solid tumors and has out-licensed the toxin for use in other conjugate therapeutics.

Like auristatins and maytansine, which are used as payloads in antibody-drug conjugates (ADCs), tubulysin is a microtubule-disrupting agent.